A survey on drug interactions and determinant factors in outpatient prescriptions for copd patients at Cho Ray Hospital in 2023

Tóm tắt

This study aimed to characterize the prevalence, clinical features, and associated risk factors of clinically significant drug-drug interactions (DDIs) among outpatients with chronic obstructive pulmonary disease (COPD). A retrospective cross-sectional analysis was performed on 500 outpatient prescriptions collected from July to December 2023 at Cho Ray Hospital. DDIs were identified using the Drugs.com and Medscape.com databases and categorized based on severity: major, moderate, or minor. Patient characteristics, including age, sex, number of comorbidities, and total number of prescribed medications, were analyzed as potential risk factors. Statistical analysis was conducted using SPSS 22.0, with logistic regression modeling employed to ascertain significant associations.

The prevalence of DDIs was found to be 48.6% according to Drugs.com and 44.2% based on Medscape. Clinically significant DDIs, defined as major or moderate interactions, were present in 21.8% of all prescriptions, with major and moderate interactions accounting for 6.4% and 15.4%, respectively. Multivariate logistic regression revealed that polypharmacy, defined as the use of five or more medications, was associated with a 3.2-fold increased risk of clinically significant DDIs (p<0.001). Furthermore, patients aged 65 years or older demonstrated a 2.0-fold higher risk (p=0.012). These findings indicate a considerable prevalence of clinically significant DDIs in this patient population, particularly among older adults and those receiving multiple medications. The results underscore the need for enhanced DDI prevention strategies, such as integrating clinical pharmacists into the prescription monitoring process, to improve patient safety.